abrdn Life Sciences Investors (HQL) Competitors $13.41 +0.11 (+0.80%) Closing price 07/23/2025 03:59 PM EasternExtended Trading$13.40 -0.01 (-0.04%) As of 07/23/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsDividendHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock HQL vs. CET, GSBD, MFIC, NMFC, PFLT, BCSF, BBDC, AWF, HQH, and PHKShould you be buying abrdn Life Sciences Investors stock or one of its competitors? The main competitors of abrdn Life Sciences Investors include Central Securities (CET), Goldman Sachs BDC (GSBD), MidCap Financial Investment (MFIC), New Mountain Finance (NMFC), PennantPark Floating Rate Capital (PFLT), Bain Capital Specialty Finance (BCSF), Barings Bdc (BBDC), AllianceBernstein Global High Income Fund (AWF), abrdn Healthcare Investors (HQH), and PIMCO High Income Fund (PHK). These companies are all part of the "financial services" industry. abrdn Life Sciences Investors vs. Its Competitors Central Securities Goldman Sachs BDC MidCap Financial Investment New Mountain Finance PennantPark Floating Rate Capital Bain Capital Specialty Finance Barings Bdc AllianceBernstein Global High Income Fund abrdn Healthcare Investors PIMCO High Income Fund Central Securities (NYSE:CET) and abrdn Life Sciences Investors (NYSE:HQL) are both small-cap finance companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, media sentiment, analyst recommendations, risk, dividends and valuation. Is CET or HQL a better dividend stock? Central Securities pays an annual dividend of $2.30 per share and has a dividend yield of 4.7%. abrdn Life Sciences Investors pays an annual dividend of $1.89 per share and has a dividend yield of 14.1%. Do institutionals & insiders have more ownership in CET or HQL? 8.7% of Central Securities shares are owned by institutional investors. Comparatively, 32.2% of abrdn Life Sciences Investors shares are owned by institutional investors. 9.5% of Central Securities shares are owned by company insiders. Comparatively, 10.1% of abrdn Life Sciences Investors shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Which has more risk & volatility, CET or HQL? Central Securities has a beta of 0.82, suggesting that its stock price is 18% less volatile than the S&P 500. Comparatively, abrdn Life Sciences Investors has a beta of 0.74, suggesting that its stock price is 26% less volatile than the S&P 500. Is CET or HQL more profitable? Company Net Margins Return on Equity Return on Assets Central SecuritiesN/A N/A N/A abrdn Life Sciences Investors N/A N/A N/A Which has higher earnings and valuation, CET or HQL? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCentral Securities$296.20M4.73N/AN/AN/Aabrdn Life Sciences InvestorsN/AN/AN/AN/AN/A Does the media prefer CET or HQL? In the previous week, Central Securities and Central Securities both had 1 articles in the media. Central Securities' average media sentiment score of 1.94 beat abrdn Life Sciences Investors' score of 1.82 indicating that Central Securities is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Central Securities 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive abrdn Life Sciences Investors 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive SummaryCentral Securities and abrdn Life Sciences Investors tied by winning 3 of the 6 factors compared between the two stocks. Get abrdn Life Sciences Investors News Delivered to You Automatically Sign up to receive the latest news and ratings for HQL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding HQL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HQL vs. The Competition Export to ExcelMetricabrdn Life Sciences InvestorsFIN IndustryFinance SectorNYSE ExchangeMarket Cap$384M$3.82B$12.15B$20.89BDividend Yield14.21%6.64%5.55%3.62%P/E RatioN/AN/A19.1727.93Price / SalesN/A23.1026.3872.74Price / CashN/A15.3921.6622.61Price / BookN/A1.132.334.70Net IncomeN/A$165.11M$997.25M$993.85M7 Day Performance1.75%0.24%1.39%1.99%1 Month Performance4.98%1.19%4.45%5.85%1 Year Performance-11.92%1.66%542.15%13.36% abrdn Life Sciences Investors Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HQLabrdn Life Sciences InvestorsN/A$13.41+0.8%N/A-12.4%$384MN/A0.00N/APositive NewsCETCentral SecuritiesN/A$48.05-0.2%N/A+9.3%$1.39B$296.20M0.006GSBDGoldman Sachs BDC1.2981 of 5 stars$11.84+0.3%$12.00+1.4%-21.9%$1.39B$434.37M26.31N/APositive NewsMFICMidCap Financial Investment2.1415 of 5 stars$13.19+0.2%$14.00+6.1%-14.5%$1.23B$113.46M10.64N/ANews CoverageAnalyst ForecastNMFCNew Mountain Finance1.7162 of 5 stars$10.72-0.6%$10.67-0.5%-13.3%$1.16B$371.67M10.72N/APFLTPennantPark Floating Rate Capital3.3059 of 5 stars$10.83+0.8%$10.92+0.8%-5.7%$1.07B$84.09M7.73658BCSFBain Capital Specialty Finance1.9363 of 5 stars$15.58+0.6%$16.50+5.9%-6.1%$1.01B$292.65M8.961,000Positive NewsBBDCBarings Bdc2.3727 of 5 stars$9.53+0.1%$9.67+1.5%-5.1%$1.00B$286.17M10.1326AWFAllianceBernstein Global High Income FundN/A$11.09+0.3%N/A+4.5%$955.86M$70.19M0.00N/AHQHabrdn Healthcare InvestorsN/A$15.77-0.1%N/A-12.8%$849.10MN/A0.00147,000Positive NewsPHKPIMCO High Income FundN/A$4.79-0.8%N/A+1.1%$821.44MN/A0.00147,000 Related Companies and Tools Related Companies CET Competitors GSBD Competitors MFIC Competitors NMFC Competitors PFLT Competitors BCSF Competitors BBDC Competitors AWF Competitors HQH Competitors PHK Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:HQL) was last updated on 7/24/2025 by MarketBeat.com Staff From Our PartnersA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredBREAKING: The House just passed 3 pro-crypto bills!Experts Believe Altcoin Season is Here! With this new legislation in effect, crypto experts across the coun...Crypto 101 Media | SponsoredFREE GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...GoldCo Precious Metals | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding abrdn Life Sciences Investors Please log in to your account or sign up in order to add this asset to your watchlist. Share abrdn Life Sciences Investors With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
